Mevacor OTC Study Shows High-Risk Users Will “Upstream,” Merck Says
This article was originally published in The Tan Sheet
Executive Summary
Merck's educational strategy for potential over-the counter sale of 20 mg Mevacor (lovastatin) will prevent rather than increase undertreatment among people who should be using more aggressive statin therapy, the firm contends
You may also be interested in...
Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
The top three statins - Zocor, Lipitor, and Pravachol -have roughly equivalent low risks of rhabdomyolysis, according to a study of health plan prescription data released by the Journal of the American Medical Association Nov. 23
NCEP Statin Recommendations Challenged By CSPI, Researchers
The Center for Science in the Public Interest and a cohort of researchers are calling for an independent re-evaluation of the scientific data used by NIH's National Cholesterol Education Program to justify lowering the threshold for statin therapy
CARDS Researchers Bet On Statins For CVD Prevention In Type 2 Diabetics
Treatment guidelines for statin use among diabetics should be reexamined in light of a recently published study on atorvastatin (Pfizer's Lipitor), researchers say